Anebulo Pharmaceuticals Inc
ANEB2.170USD
-0.040-1.81%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
89.15MMarket Cap
LossP/E TTM
More Details of Anebulo Pharmaceuticals Inc Company
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous administration. Selonabant is intended to rapidly reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. It is also prioritizing the advancement of a selonabant intravenous (IV) formulation as a potential treatment for pediatric patients with cannabis-induced CNS depression.
Anebulo Pharmaceuticals Inc Info
Ticker SymbolANEB
Company nameAnebulo Pharmaceuticals Inc
IPO dateMay 07, 2021
CEO- -
Number of employees2
Security typeOrdinary Share
Fiscal year-endMay 07
AddressC/O Anebulo Pharmaceuticals, Inc.
CityLAKEWAY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code78734
Phone17372035270
Websitehttps://www.anebulo.com/
Ticker SymbolANEB
IPO dateMay 07, 2021
CEO- -
Company Executives of Anebulo Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Aron R. English
Mr. Aron R. English
Independent Director
Independent Director
4.65M
--
Dr. Nathaniel (Nat) Calloway
Dr. Nathaniel (Nat) Calloway
Independent Director
Independent Director
--
--
Mr. Daniel George
Mr. Daniel George
Part Time Chief Financial Officer
Part Time Chief Financial Officer
--
--
Dr. Kenneth C. Cundy, Ph.D.
Dr. Kenneth C. Cundy, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Jason Aryeh
Mr. Jason Aryeh
Independent Director
Independent Director
--
--
Mr. Bimal Shah
Mr. Bimal Shah
Independent Director
Independent Director
--
--
Mr. Richard Anthony Cunningham
Mr. Richard Anthony Cunningham
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Ms. Areta Kupchyk
Ms. Areta Kupchyk
Independent Director
Independent Director
--
--
Dr. Kenneth Lin
Dr. Kenneth Lin
Independent Director
Independent Director
--
--
Dr. Joseph F. Lawler
Dr. Joseph F. Lawler
Non-Executive Independent Chairman of the Board, Founder
Non-Executive Independent Chairman of the Board, Founder
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Aron R. English
Mr. Aron R. English
Independent Director
Independent Director
4.65M
--
Dr. Nathaniel (Nat) Calloway
Dr. Nathaniel (Nat) Calloway
Independent Director
Independent Director
--
--
Mr. Daniel George
Mr. Daniel George
Part Time Chief Financial Officer
Part Time Chief Financial Officer
--
--
Dr. Kenneth C. Cundy, Ph.D.
Dr. Kenneth C. Cundy, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Mr. Jason Aryeh
Mr. Jason Aryeh
Independent Director
Independent Director
--
--
Mr. Bimal Shah
Mr. Bimal Shah
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
22NW, LP
37.65%
Lawler (Joseph F.)
29.21%
English (Aron R)
11.33%
Nantahala Capital Management, LLC
7.39%
Mangrove Partners
6.15%
Other
8.28%
Shareholders
Shareholders
Proportion
22NW, LP
37.65%
Lawler (Joseph F.)
29.21%
English (Aron R)
11.33%
Nantahala Capital Management, LLC
7.39%
Mangrove Partners
6.15%
Other
8.28%
Shareholder Types
Shareholders
Proportion
Individual Investor
40.54%
Investment Advisor/Hedge Fund
38.21%
Hedge Fund
14.04%
Research Firm
0.98%
Investment Advisor
0.80%
Venture Capital
0.05%
Other
5.38%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
35
22.22M
55.29%
--
2025Q3
36
22.22M
55.72%
-372.18K
2025Q2
28
22.59M
55.73%
-26.30K
2025Q1
27
22.62M
55.47%
-171.00K
2024Q4
24
22.57M
18.48%
+15.23M
2024Q3
25
7.34M
30.68%
+35.91K
2024Q2
25
7.31M
30.58%
+1.43K
2024Q1
26
7.31M
31.29%
-807.06K
2023Q4
26
7.29M
28.51%
+229.11K
2023Q3
24
7.06M
28.44%
+18.61K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
22NW, LP
15.47M
37.65%
--
--
Jun 30, 2025
Lawler (Joseph F.)
12.00M
29.21%
--
--
Sep 26, 2025
English (Aron R)
4.65M
11.33%
--
--
Feb 24, 2025
Nantahala Capital Management, LLC
3.04M
7.39%
--
--
Jun 30, 2025
Mangrove Partners
2.53M
6.15%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
399.22K
0.97%
--
--
Jun 30, 2025
The Vanguard Group, Inc.
215.95K
0.53%
+11.41K
+5.58%
Jun 30, 2025
Geode Capital Management, L.L.C.
205.72K
0.5%
+302.00
+0.15%
Jun 30, 2025
Ikarian Capital LLC
157.72K
0.38%
--
--
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Anebulo Pharmaceuticals Inc?
The top five shareholders of Anebulo Pharmaceuticals Inc are:
22NW, LP holds 15.47M shares, accounting for 37.65% of the total shares.
Lawler (Joseph F.) holds 12.00M shares, accounting for 29.21% of the total shares.
English (Aron R) holds 4.65M shares, accounting for 11.33% of the total shares.
Nantahala Capital Management, LLC holds 3.04M shares, accounting for 7.39% of the total shares.
Mangrove Partners holds 2.53M shares, accounting for 6.15% of the total shares.
22NW, LP holds 15.47M shares, accounting for 37.65% of the total shares.
Lawler (Joseph F.) holds 12.00M shares, accounting for 29.21% of the total shares.
English (Aron R) holds 4.65M shares, accounting for 11.33% of the total shares.
Nantahala Capital Management, LLC holds 3.04M shares, accounting for 7.39% of the total shares.
Mangrove Partners holds 2.53M shares, accounting for 6.15% of the total shares.
What are the top three shareholder types of Anebulo Pharmaceuticals Inc?
The top three shareholder types of Anebulo Pharmaceuticals Inc are:
22NW, LP
Lawler (Joseph F.)
English (Aron R)
22NW, LP
Lawler (Joseph F.)
English (Aron R)
How many institutions hold shares of Anebulo Pharmaceuticals Inc (ANEB)?
As of 2025Q4, 35 institutions hold shares of Anebulo Pharmaceuticals Inc, with a combined market value of approximately 22.22M, accounting for 55.29% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -0.43%.
What is the biggest source of revenue for Anebulo Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Anebulo Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
